JPRN-UMIN000046974招募中未知
Phase I / II Clinical Trial of GAIA-102 for advanced and relapse NSCLC - GAIA-102-LC01
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Patients with symptomatological cranial nerve system metastasis. If treatment for cranial nerve system metastasis has already been performed and the neurologically recovered state has been maintained for 2 weeks or more before registration, registration is possible. (2) Patients diagnosed with cancerous meningitis (3) Patients who received allogeneic hematopoietic stem cell transplantation (4) Patients with active autoimmune disease
研究者
相似试验
招募中
1 期
Phase I / II Clinical Trial of GAIA-102 for advanced and relapse NSCLCadvanced and relapse NSCLCCarcinoma, Non-Small-Cell LungJPRN-jRCT2073210080Okamoto Isamu38
招募中
1 期
Phase I clinical trial of GAIA-102 for refractory/relapse neuroblastomas or malignant pediatric solid tumors with lung metastases.refractory/relapse neuroblastoma or pediatric solid tumors with lung metastasesJPRN-jRCT2073220054Kawakubo Naonori36
招募中
2 期
Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with tri-weekly docetaxel (D) followed by doxorubicin, 5-fluorouracil, and cyclophosphamide (FEC) or docetaxel with concurrent use of capecitabine (TX) followed by doxorubicin, cyclophosphamide, and capecitabine (CEX) in women with locally advanced triple-negative breast cancerntreated women with triple negative breast cancer (T1c-4NxM0)JPRN-UMIN000018722Japanese Red Cross Society Himeji Hospital84
进行中（未招募）
不适用
A randomized phase II clinical trial on the efficacy of axitinib as a monotherapy or in combination with lomustine for the treatment of patients with recurrent glioblastomaEUCTR2011-000900-16-BEZ BRUSSE
进行中（未招募）
2 期
Phase IIa study (doctor-led trial) for the efficacy and safety of SJP-0008 in central retinal artery occlusiocentral retinal artery occlusionJPRN-jRCT2021190013akazawa Toru20